Ivar Anders Eide
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Ivar Anders Eide has a total of 28 co-authors. Here are the top co-authors by number of shared publications:
Anders Hartmann
Department of Transplantation Medicine, Oslo University Hospital, Rikshospitalet, Oslo, Norway
2 shared publicationsAnders Åsberg
Department of Renal Medicine, Akershus University Hospital, Lørenskog, Norway
2 shared publicationsErik B. Schmidt
Department of Cardiology, Aalborg University Hospital, Aalborg, Denmark
2 shared publicationsFinn P. Reinholt
Department of Pathology, Oslo University Hospital, Rikshospitalet, Oslo, Norway
2 shared publicationsMy Svensson
Department of Renal Medicine, Akershus University Hospital, Lørenskog, Norway
2 shared publicationsTrond Jenssen
Department of Transplantation Medicine, Oslo University Hospital, Rikshospitalet, Oslo, Norway
2 shared publications
Latest Publications
- Open Access
Marine n-3 Polyunsaturated Fatty Acids and Bone Mineral Density in Kidney Transplant Recipients: A Randomized, Placebo-Controlled Trial
Kidney transplant recipients are at high risk of progressive bone loss and low-energy fractures in the years following transplantation. Marine n-3 polyunsaturated fatty acids (n-3 PUFA) supplementation may have beneficial effects on bone strength. The Omega-3 fatty acids in Renal Transplantation (ORENTRA) trial was an investigator initiated, randomized, placebo-controlled trial investigating the effects of marine n-3 PUFA supplementation after kidney transplantation. Effects of supplementation on bone mineral density (BMD) and calcium metabolism were pre-defined secondary endpoints. Adult kidney transplant recipients (n = 132) were randomized to 2.6 g marine n-3 PUFA supplement or olive oil (control) from 8 to 52 weeks post-transplant. Dual energy X-ray absorptiometry was performed to assess changes in bone mineral density of hip, spine, and forearm, as well as trabecular bone score (TBS) of the lumbar spine. Student’s t test was used to assess between-group differences. There were no differences in ΔBMD between the two groups (intervention vs. control) at lumbar spine (−0.020 ± 0.08 vs. −0.007 ± 0.07 g/cm², p = 0.34), total hip (0.001 ± 0.03 vs. −0.005 ± 0.04, p = 0.38), or other skeletal sites in the intention-to-treat analyses. There was no difference in the change in TBS score (0.001 ± 0.096 vs. 0.009 ± 0.102, p = 0.62). Finally, no effect on biochemical parameters of mineral metabolism was seen. Results were similar when analyzed per protocol. In conclusion, we found no significant effect of 44 weeks of supplementation with 2.6 g of marine n-3 PUFA on BMD in kidney transplant recipients.
Open AccessMarine n-3 Polyunsaturated Fatty Acids and Bone Mineral Density in Kidney Transplant Recipients: A Randomized, Placebo-Controlled Trial
Kidney transplant recipients are at high risk of progressive bone loss and low-energy fractures in the years following transplantation. Marine n-3 polyunsaturated fatty acids (n-3 PUFA) supplementation may have beneficial effects on bone strength. The Omega-3 fatty acids in Renal Transplantation (ORENTRA) trial was an investigator initiated, randomized, placebo-controlled trial investigating the effects of marine n-3 PUFA supplementation after kidney transplantation. Effects of supplementation on bone mineral density (BMD) and calcium metabolism were pre-defined secondary endpoints. Adult kidney transplant recipients (n = 132) were randomized to 2.6 g marine n-3 PUFA supplement or olive oil (control) from 8 to 52 weeks post-transplant. Dual energy X-ray absorptiometry was performed to assess changes in bone mineral density of hip, spine, and forearm, as well as trabecular bone score (TBS) of the lumbar spine. Student’s t test was used to assess between-group differences. There were no differences in ΔBMD between the two groups (intervention vs. control) at lumbar spine (−0.020 ± 0.08 vs. −0.007 ± 0.07 g/cm², p = 0.34), total hip (0.001 ± 0.03 vs. −0.005 ± 0.04, p = 0.38), or other skeletal sites in the intention-to-treat analyses. There was no difference in the change in TBS score (0.001 ± 0.096 vs. 0.009 ± 0.102, p = 0.62). Finally, no effect on biochemical parameters of mineral metabolism was seen. Results were similar when analyzed per protocol. In conclusion, we found no significant effect of 44 weeks of supplementation with 2.6 g of marine n-3 PUFA on BMD in kidney transplant recipients.
- 1 March 2019
- Published by Elsevier in Transplantation Proceedings
- Vol. 51 (2) , 470-474
Contraceptive Choices and Counseling in Norwegian Female Renal Transplant Recipients
- 1 March 2019
- Published by Elsevier in Transplantation Proceedings
- Vol. 51 (2) , 470-474
Contraceptive Choices and Counseling in Norwegian Female Renal Transplant Recipients
- Open Access
- 20 August 2018
- Published by Elsevier in American Journal of Transplantation
- Vol. 19 (3) , 790-800
Effects of marine n-3 fatty acid supplementation in renal transplantation: A randomized controlled trial
- 20 August 2018
- Published by Elsevier in American Journal of Transplantation
- Vol. 19 (3) , 790-800
Open AccessEffects of marine n-3 fatty acid supplementation in renal transplantation: A randomized controlled trial
- 1 March 2018
- Published by Elsevier in Journal of Renal Nutrition
- Vol. 28 (2) , 118-124
Development of Kidney Transplant Fibrosis Is Inversely Associated With Plasma Marine Fatty Acid Level
- 1 March 2018
- Published by Elsevier in Journal of Renal Nutrition
- Vol. 28 (2) , 118-124
Development of Kidney Transplant Fibrosis Is Inversely Associated With Plasma Marine Fatty Acid Level